Also known as: Nvidia, NVIDIA
NVIDIA is a computing infrastructure company that pioneered accelerated computing and AI. Its platforms span data center, gaming, professional visualization, automotive, and robotics applications.
Servier agreed to acquire Day One for $2.5B, gaining an approved childhood brain tumor drug and pipeline assets. SCRI and MSD launched a collaboration to expand community oncology trial access, while Recursion took full ownership of REC-102 as Nvidia and Novo exited.
Virginia Tech received a $20M NSF grant for an AI semiconductor lab; Navikenz raised $7.5M and ChemT Biotechnology raised $4M in seed funding. The investments support AI-driven research and manufacturing.
AI drug discovery is moving from hype to proof in 2026, with multi-billion-dollar partnerships, new joint initiatives, and major investments accelerating AI-native biotech pipelines and data-driven deals.
U.S. biotech IPOs have returned 55% on average this year, crushing the broader IPO market. Nvidia exited Recursion as ARK Invest bought shares, while Revolution Medicines gained 132% on strong pancreatic cancer data.
New reports project AI in drug discovery at $17.56B by 2031 (28.1% CAGR) or $2.29B by 2031 (12.49% CAGR). North America led in 2025, oncology topped therapy areas, and talent shortages persist.
Anthropic launched Claude Science, an AI workbench with 60+ skills and databases, and began preclinical programs for neglected diseases. A demo analyzed 100 rare genetic diseases in under an hour.
Qiagen launched the QIA Agent AI assistant for lab workflows and expanded its NVIDIA collaboration in bioinformatics. Valuation narratives peg the stock as undervalued, with fair value estimates around $53.53–$54.61, though momentum and funding risks remain.
Novo Nordisk partners with OpenAI to speed drug discovery, with pilots by 2026. AI is moving beyond hype into pharma R&D, reflected in major collaborations and new FDA guidance.
At the ADA Scientific Sessions, Novo Nordisk's Wegovy pill surpassed 3 million prescriptions within five months, while Structure Therapeutics and AstraZeneca shared mid-stage GLP-1 data targeting a 2029 launch. The US FDA approved TRUQAP as the first targeted treatment for PTEN-deficient metastatic prostate cancer, reducing disease progression risk by 19% in the CAPItello-281 trial. Meanwhile, two major genomic atlas projects—a 4,098-genome infant gut bacteria catalog and Basecamp Research's Trillion Gene Atlas—aim to advance precision probiotics and AI-driven drug discovery, respectively.
AI is reshaping pharma work by adding roles in drug discovery, commercial analytics and in-house AI teams rather than driving major job losses. Companies are also moving toward always-on intelligence as faster market shifts expose the limits of siloed, episodic insight models.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04834934 |
Artificial Intelligence - SARS-CoV-2 (COVID-19) Risk Evaluation |
COMPLETED |
